Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NSE - Delayed Quote INR

Marksans Pharma Limited (MARKSANS.NS)

216.03
-12.34
(-5.40%)
At close: April 25 at 3:30:03 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
24,711,860
21,741,950
18,496,190
14,801,240
13,683,740
Cost of Revenue
11,444,630
10,942,390
9,580,770
7,168,170
6,185,970
Gross Profit
13,267,230
10,799,560
8,915,420
7,633,070
7,497,770
Operating Expense
8,907,400
6,904,920
5,786,410
5,465,710
4,310,640
Operating Income
4,359,830
3,894,640
3,129,010
2,167,360
3,187,130
Net Non Operating Interest Income Expense
207,210
225,840
29,090
-24,730
-68,270
Pretax Income
4,881,470
4,235,260
3,376,530
2,475,110
3,021,640
Tax Provision
1,186,110
1,086,310
723,320
606,970
636,260
Net Income Common Stockholders
3,683,200
3,137,000
2,663,080
1,845,690
2,385,380
Diluted NI Available to Com Stockholders
3,683,200
3,137,000
2,663,080
1,845,690
2,385,380
Basic EPS
8.13
6.92
6.41
4.51
5.83
Diluted EPS
8.13
6.92
6.41
4.51
5.83
Basic Average Shares
452,850.77
453,160
415,400
409,310
409,310
Diluted Average Shares
452,850.77
453,160
415,400
409,310
409,310
Rent Expense Supplemental
--
122,430
129,150
47,440
123,090
Total Expenses
20,352,030
17,847,310
15,367,180
12,633,880
10,496,610
Net Income from Continuing & Discontinued Operation
3,683,200
3,137,000
2,663,080
1,845,690
2,385,380
Normalized Income
3,688,203.89
3,141,914.59
2,862,880.30
1,822,239.28
2,485,069.50
Interest Income
--
337,870
120,370
59,730
11,590
Interest Expense
130,660
112,030
57,460
53,900
34,670
Net Interest Income
207,210
225,840
29,090
-24,730
-68,270
EBIT
5,012,130
4,347,290
3,433,990
2,529,010
3,056,310
EBITDA
5,829,100
5,089,990
3,952,520
2,976,770
3,417,820
Reconciled Cost of Revenue
11,444,630
10,942,390
9,580,770
7,168,170
6,185,970
Reconciled Depreciation
816,970
742,700
518,530
447,760
361,510
Net Income from Continuing Operation Net Minority Interest
3,683,200
3,137,000
2,663,080
1,845,690
2,385,380
Total Unusual Items Excluding Goodwill
-6,610
-6,610
-254,270
31,070
-126,280
Total Unusual Items
-6,610
-6,610
-254,270
31,070
-126,280
Normalized EBITDA
5,835,710
5,096,600
4,206,790
2,945,700
3,544,100
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-1,606.11
-1,695.41
-54,469.70
7,619.28
-26,590.50
3/31/2021 - 7/19/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SMSPHARMA.NS SMS Pharmaceuticals Limited
240.35
-0.71%
 
SENORES.NS SENORES PHARMACEUTICALS L
517.05
-2.90%
 
SANOFICONR.NS SANOFI CONS HEALTHC IND L
4,939.00
+0.03%
 
KOPRAN.NS Kopran Limited
190.58
-4.16%
 
SANOFI.NS Sanofi India Limited
6,273.00
-4.51%
 
BMY Bristol-Myers Squibb Company
47.90
-1.62%
 
LLY Eli Lilly and Company
884.54
+2.89%